

<b>Allo:</b> Allogeneic Stem Cell Transplant	<b>GIMEMA:</b> The Italian myeloma clinical trials group	<b>MRD:</b> Minimal Residual Disease	<b>RMPT:</b> Revlimid, Melphalan, Prednisone, Thalidomide
<b>Auto:</b> Autologous Stem Cell Transplant	<b>GMMG:</b> The German myeloma clinical trials group	<b>MRI:</b> Magnetic Resonance Imaging	<b>RRMM:</b> Relapsed/Refractory Multiple Myeloma
<b>ASCT:</b> Autologous Stem Cell Transplant	<b>GVHD:</b> Graft Versus Host Disease	<b>mSMART:</b> Mayo Stratification of Myeloma and Risk-Adapted Therapy	<b>RQPC:</b> Real-time Quantitative Polymerase Chain Reaction (DNA test)
<b>B2M:</b> Beta 2 Microglobulin	<b>HDAC:</b> Histone Deacetylase	<b>MTD:</b> Maximum Tolerated Dose	<b>RVD:</b> Revlimid, Velcade, Dexamethasone
<b>BiRD:</b> Biacin, Revlimid, Dexamethasone	<b>HDT:</b> High-Dose Therapy	<b>NA or N/A:</b> Not Available	<b>sCR:</b> Stringent Complete Response (CR plus normal free light chain ratio and no clonal plasma cells)
<b>BMT:</b> CTN Bone Marrow Transplant Clinical Trials Network	<b>HOVON:</b> The Dutch clinical trials myeloma group	<b>nCR:</b> Near-Complete Response	<b>SCT:</b> Stem Cell Transplant
<b>BP:</b> Bisphosphonate	<b>HR:</b> Hazard Ratio (statistical term)	<b>NDMM:</b> Newly Diagnosed Multiple Myeloma	<b>SD:</b> Stable Disease
<b>CALGB:</b> Cancer and Leukemia Group B (a US cooperative clinical trials group)	<b>HRSMM:</b> High-Risk Smoldering Multiple Myeloma	<b>NGF:</b> Next-Generation Flow (new 8-color flow cytometry test with software for myeloma)	<b>SMM:</b> Smoldering Multiple Myeloma
<b>CBC:</b> Complete Blood Count	<b>IEP:</b> Immunoelectrophoresis	<b>NGS:</b> Next-Generation Sequencing (new DNA-sequencing test)	<b>SPM:</b> Second Primary Malignancy
<b>CD34:</b> Cluster of Differentiation 34 (a cell surface protein on hematopoietic stem cells)	<b>IFE:</b> Immunofixation Electrophoresis	<b>NR:</b> Not Reached	<b>SQ:</b> Subcutaneous (sometimes abbreviated SC)
<b>CI:</b> Confidence Interval (statistical term)	<b>IFM:</b> The French myeloma clinical trials group	<b>ONJ:</b> Osteonecrosis of the Jaw	<b>SRE:</b> Skeletal-Related Event
<b>CR:</b> Complete Remission (100% reduction in monoclonal protein)	<b>Ig:</b> Immunoglobulin	<b>ORR:</b> Overall Response Rate	<b>TMI:</b> Too Much Information
<b>Cr:</b> Creatinine	<b>IM:</b> Intramuscular (shot or injection into the muscle)	<b>OS:</b> Overall Survival	<b>TTP:</b> Time to Progression
<b>CRAB:</b> Calcium Renal Anemia Bone Disease—criteria for diagnosis of active myeloma	<b>IMWG:</b> International Myeloma Working Group Acronym Meaning	<b>PAD:</b> Velcade (formerly PS-341), Adriamycin, Dexamethasone	<b>VAD:</b> Vincristine, Adriamycin, Dexamethasone (old standard induction therapy)
<b>CRP:</b> C-Reactive Protein	<b>ISS:</b> International Staging System	<b>PBSCT:</b> Peripheral Blood Stem Cell Transplant	<b>VCF:</b> Vertebral Compression Fracture
<b>CT:</b> Computerized Tomography scan (3-D x-ray)	<b>IV:</b> Intravenous (injection into the vein)	<b>PCLI:</b> Plasma Cell Labeling Index	<b>VDT-PACE:</b> Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
<b>CyBorD:</b> Cytoxan, Velcade (Bortezomib), Dexamethasone, also written VCd	<b>KRD:</b> Kyprolis (carfilzomib), Revlimid, Dexamethasone	<b>PCR:</b> Polymerase Chain Reaction (DNA test, also called ASO PCR or Allele-Specific Oligonucleotide PCR)	<b>VEGF:</b> Vascular Endothelial Growth Factor
<b>DCEP:</b> Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin	<b>MEL 200:</b> The dose of melphalan administered in ASCT: 200 mg of melphalan per square meter of body mass	<b>PET:</b> Positron Emission Tomography	<b>VGPR:</b> Very Good Partial Remission (at least 90% reduction in monoclonal protein)
<b>DEX:</b> Dexamethasone	<b>MGUS:</b> Monoclonal Gammopathy of Undetermined Significance	<b>PET/CT:</b> PET combined with a CT scan	<b>VRd:</b> Velcade, Revlimid, Low-Dose Dexamethasone
<b>DPACE:</b> Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide	<b>MP:</b> Melphalan & Prednisone	<b>PETHEMA:</b> The Spanish myeloma clinical trials group	<b>VTD:</b> Velcade, Thalidomide, Dexamethasone
<b>EFS:</b> Event-Free Survival	<b>MPR:</b> Melphalan, Prednisone, Revlimid	<b>PFS:</b> Progression-Free Survival	<b>WBLD CT:</b> Whole-Body Low-Dose CT
<b>EMD:</b> Extramedullary Disease (myeloma that grows outside the bone marrow)	<b>MPT:</b> Melphalan, Prednisone, Thalidomide	<b>PN:</b> Peripheral Neuropathy	<b>WBLD:</b> MRI Whole-Body Low-Dose MRI
<b>FISH:</b> Fluorescent In Situ Hybridization	<b>MR:</b> Minimal Response (between 25% and 50% response to a drug or regimen in a clinical trial)	<b>PR:</b> Partial Remission (at least 50% reduction in monoclonal protein) RCT Randomized Clinical Trial	<b>WM:</b> Waldenstrom's Macroglobulinemia
<b>FLC:</b> Free Light Chain	<b>MRC:</b> Medical Research Council (UK myeloma clinical trials group)	<b>REVLDEX:</b> Revlimid, Low dose Dexamethasone	<b>ZOL:</b> Zoledronic acid (Zometa)